Bruker Corporation (FRA:BKD)
Germany · Delayed Price · Currency is EUR | Market Cap | 7.49B +46.8% |
| Revenue (ttm) | 3.00B +0.4% |
| Net Income | -31.57M |
| EPS | -0.21 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 24.98 |
| Dividend | 0.17 (0.35%) |
| Ex-Dividend Date | Mar 23, 2026 |
| Volume | n/a |
| Open | 48.77 |
| Previous Close | 49.78 |
| Day's Range | 48.24 - 49.60 |
| 52-Week Range | 24.80 - 50.45 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 6, 2026 |
About Bruker
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron par... [Read more]
News
Jefferies semis analyst holds an analyst/industry conference call
Analysts Peterson, Stanton and Curtis, along with Mark Munch, President of Bruker (BRKR) Nano Group, discuss Bruker’s capabilities and exposure within the Semiconductor ecosystem, including Semiconduc...
Bruker Launches new timsMRMS Mass Spectrometry Platform for Unique Ultra-Complex Mixture Applications in the Energy Industry
SAN DIEGO--(BUSINESS WIRE)---- $BRKR #BRKR--At ASMS, Bruker Corporation (Nasdaq: BRKR) announced the launch of the new timsMRMS system, designed to empower researchers in petroleomics, sustainable fue...
Bruker price target raised to $65 from $49 at BofA
BofA raised the firm’s price target on Bruker (BRKR) to $65 from $49 and keeps a Buy rating on the shares. Diagnostic tools have rallied almost 10% in the last…
Wolfe assumes ‘really expensive’ Bruker with a Peer Perform
As previously reported, Wolfe Research downgraded Bruker (BRKR) to Peer Perform from Outperform with no price target as the analyst assumed coverage of the stock. Bruker “has gotten really expensive…
Bruker assumed at Peer Perform from Outperform at Wolfe Research
Wolfe Research downgraded Bruker (BRKR) to Peer Perform from Outperform with no price target as the analyst assumed coverage of the stock.
Bruker announces launch of timsMRMS system
At ASMS, Bruker (BRKR) Corporation announced the launch of the timsMRMS system. Frank Laukien, PhD, Bruker’s President and CEO, said: “Proteoforms are the fundamental unit of molecular disease. A sing...
Bruker Announces Major Strides in 4D Proteomics Performance, Further Advances In Intact and Top-Down Functional Proteoform Analysis, and Innovations in Hybrid Qual/Quant 4D Metabolomics – all to Enable Deeper Insights into Disease Biology
SAN DIEGO--(BUSINESS WIRE)---- $BRKR #BRKR--At ASMS, Bruker Corporation (Nasdaq: BRKR) announced the launch of the unique timsMRMS system, bringing the power of trapped ion mobility separation to ultr...
Bruker participates in a conference call with Jefferies
Life Science Tools & Diagnostics Analyst Peterson, along with Mark Munch, PhD, President of Bruker (BRKR) Nano Group discuss BRKR’s capabilities and positioning within the semi space on a conference…
Bruker announces commissioning of BioSpec 18 Tesla preclinical MRi
Bruker (BRKR) Corporation announced the commissioning of a novel BioSpec 18 Tesla preclinical MRI at the Champalimaud Foundation in Lisbon, Portugal. The BioSpec 18T system provides increased spatial ...
Champalimaud Foundation's Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRI
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation announced the commissioning of a novel BioSpec™ 18 Tesla preclinical MRI, the world's highest-field horizontal-bore MRI system, at...
Bruker Transcript: AGM 2026
The meeting confirmed a quorum, elected three directors through 2029, approved 2025 executive compensation, and ratified the appointment of independent auditors for 2026. Stockholders were invited to submit questions before adjournment.
Bruker price target raised to $45 from $40 at Stifel
Stifel analyst Daniel Arias raised the firm’s price target on Bruker (BRKR) to $45 from $40 and keeps a Hold rating on the shares.
Bruker price target raised to $45 from $43 at TD Cowen
TD Cowen raised the firm’s price target on Bruker (BRKR) to $45 from $43 and keeps a Hold rating on the shares. The firm updated its odel following Q1 results…
Bruker price target raised to $45 from $40 at UBS
UBS raised the firm’s price target on Bruker (BRKR) to $45 from $40 and keeps a Neutral rating on the shares.
Bruker price target raised to $53 from $45 at Barclays
Barclays analyst Luke Sergott raised the firm’s price target on Bruker (BRKR) to $53 from $45 and keeps an Overweight rating on the shares.
Bruker price target raised to $44 from $40 at Citi
Citi raised the firm’s price target on Bruker (BRKR) to $44 from $40 and keeps a Neutral rating on the shares.
Bruker reports Q1 adjusted EPS 31c, consensus 23c
Reports Q1 revenue $823.4M, consensus $795.67M. Frank H. Laukien, Bruker’s (BRKR) President and CEO, commented: “While US academic demand, tariff and currency headwinds still pressured our first quart...
Bruker backs FY26 adjusted EPS view $2.10-$2.15, consensus $2.12
06:35 EDT Bruker (BRKR) backs FY26 adjusted EPS view $2.10-$2.15, consensus $2.12
Bruker Earnings Call Transcript: Q1 2026
Q1 2026 results exceeded expectations with strong bookings in AI-driven and security segments, despite U.S. academic and currency headwinds. Guidance for FY2026 is reaffirmed, with margin expansion and EPS growth driven by cost savings and innovation momentum.
Bruker Earnings release: Q1 2026
Bruker released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Bruker Slides: Q1 2026
Bruker has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Bruker Quarterly report: Q1 2026
Bruker has published its Q1 2026 quarterly earnings report on May 6, 2026.
Bruker Reports First Quarter 2026 Financial Results
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced financial results for the three months ended March 31, 2026. Frank H. Laukien, Bruker's President a...
Bruker Announces Date and Time of First Quarter 2026 Earnings Release and Webcast
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced it will report first quarter 2026 financial results before market opening on Wednesday, May 6, 2026...
Bruker to showcase updates from Bruker Spatial Biology at AACR meeting
Bruker (BRKR) Corporation announced new updates from Bruker Spatial Biology to be showcased at the 2026 American Association for Cancer Research Annual Meeting. At AACR, Bruker Spatial Biology will hi...